

1 **Title**

2 Nuclear NAD⁺-biosynthetic enzyme NMNAT1 facilitates survival of developing retinal neurons

3

4 **Authors**

5

6 David Sokolov¹

7 Emily Sechrest^{1,2}

8 Yekai Wang^{1,3}

9 Connor Nevin¹

10 Jianhai Du^{1,3}

11 Saravanan Kolandaivelu^{1,3,*}

12

13 **Affiliations**

14

15 ¹Department of Ophthalmology and Visual Sciences, Eye Institute, One Medical Center Drive,
16 West Virginia University, Morgantown, WV, 26506-9193, USA

17 ²Department of Pharmaceutical Sciences, One Medical Center Drive, West Virginia University,
18 Morgantown, WV, 26506-9193, USA

19 ³Department of Biochemistry, One Medical Center Drive, West Virginia University,
20 Morgantown, WV, 26506-9193, USA

21 *Corresponding Author, kolandaivelus@hsc.wvu.edu

22 **ABSTRACT**

23

24 Despite mounting evidence that the mammalian retina is exceptionally reliant on proper NAD⁺
25 homeostasis for health and function, the specific roles of subcellular NAD⁺ pools in retinal
26 development, maintenance, and disease remain obscure. Here, we show that deletion of the
27 nuclear-localized NAD⁺ synthase nicotinamide mononucleotide adenylyltransferase-1
28 (NMNAT1) in the developing murine retina causes early and severe degeneration of
29 photoreceptors and select inner retinal neurons via multiple distinct cell death pathways. This
30 severe phenotype is associated with disruptions to retinal central carbon metabolism, purine
31 nucleotide synthesis, and amino acid pathways. Furthermore, large-scale transcriptomics reveals
32 dysregulation of a collection of photoreceptor and synapse-specific genes in NMNAT1 knockout
33 retinas prior to detectable morphological or metabolic alterations. Collectively, our study reveals
34 previously unrecognized complexity in NMNAT1-associated retinal degeneration and suggests a
35 yet-undescribed role for NMNAT1 in gene regulation during photoreceptor terminal
36 differentiation.

37

38

39

40

41

42

43

44

45 INTRODUCTION

46

47 Nicotinamide adenine dinucleotide (NAD⁺) is a ubiquitous cellular metabolite with an ever-
48 expanding palette of biological functions across all kingdoms of life. In addition to serving a
49 central role in redox metabolism as an electron shuttle, NAD⁺ has well-defined roles as a
50 substrate for a host of enzymes including sirtuins (SIRTs), mono- and poly- ADP-ribose
51 polymerases (PARPs), and NAD⁺ glycohydrolases (CD38, CD157, and SARM1). Collectively,
52 these roles implicate NAD⁺ metabolism in phenomena as diverse as aging, cell proliferation,
53 immunity, neurodegeneration, differentiation, and development (Houtkooper et al., 2010; Canto
54 et al., 2015; Nikiforov et al., 2015; Cambronne and Kraus, 2020; Navas and Carnero, 2021). A
55 relatively recent advance in the field is the notion of compartmentalized NAD⁺ metabolism—that
56 regulation of NAD⁺ in distinct subcellular compartments dictates function in diverse manners
57 (Canto et al., 2015; Nikiforov et al., 2015; Cambronne and Kraus, 2020; Navas and Carnero,
58 2021). While many aspects of this compartmentalization remain to be explored, it is now known
59 that spatiotemporal NAD⁺ regulation plays prominent roles in processes including axon
60 degeneration, circadian regulation, and adipogenesis (Cambronne and Kraus, 2020).

61

62 Among mammalian tissues, the retina appears particularly reliant on proper NAD⁺ homeostasis
63 for survival and function. This is suggested by associations between retinal NAD⁺ deficiency and
64 pathology in diverse models of retinal dysfunction (Lin et al., 2016; Williams et al., 2017) as
65 well as multiple mutations to NAD⁺- or NADP⁺-utilizing enzymes which cause blindness in
66 humans (Bowne et al., 2006; Aleman et al., 2018; Bennett et al., 2020). Among these enzymes is
67 nicotinamide adenyltransferase 1 (NMNAT1), a highly conserved, nuclear-localized protein

68 which catalyzes the adenylation of nicotinamide mononucleotide (NMN) or nicotinic acid
69 mononucleotide (NaMN) to form NAD^+ , the convergent step of all mammalian NAD^+
70 biosynthetic pathways (Nikiforov et al., 2015). To date, over 30 NMNAT1 mutations have been
71 linked to the severe blinding diseases Leber congenital amaurosis type 9 (LCA9) and related
72 cone-rod dystrophy (Perrault et al., 2012; Falk et al., 2012; Chiang et al., 2012; Koenekoop et al.,
73 2012; Coppieters et al., 2015; Nash et al., 2018). Although NMNAT1 is ubiquitously expressed,
74 and many of these mutations reduce NMNAT1 catalytic activity or stress-associated stability
75 (Falk et al., 2012; Koenekoop et al., 2012; Sasaki et al., 2015), patients with these disorders
76 rarely report extra-ocular phenotypes, a puzzling observation which is recapitulated by two
77 LCA-NMNAT1 mutant mouse models (Greenwald et al., 2016). Further puzzling is the
78 existence of two other NMNAT isoforms (Golgi-associated NMNAT2 and mitochondrial
79 NMNAT3), which are detectable in the retina (Kuribayashi et al., 2018) but have not been linked
80 to blindness. Importantly, while a crucial role for retinal NAD^+ was recently described through
81 characterization of mice conditionally lacking the NAD^+ pathway enzyme NAMPT in
82 photoreceptors (Lin et al., 2016), the significance of nuclear-synthesized NAD^+ in vision—
83 suggested by the fact that NMNAT1 is the only NAD^+ -pathway enzyme to date linked to
84 blindness—remains poorly understood.

85
86 Current results point to multiple, potentially distinct roles for NMNAT1 in the retina—*ex vivo*
87 studies suggest that NMNAT1 supports sirtuin function to facilitate the survival of retinal
88 progenitor cells (Kuribayashi et al., 2018), while ablation of NMNAT1 in mature mice results in
89 rapid death of photoreceptors mediated by the neurodegenerative NADase SARM1 (Sasaki et al.,
90 2020a). Global deletion of NMNAT1 in mice is embryonically lethal (Conforti et al., 2011),

91 suggesting non-redundant roles for nuclear NAD⁺ synthesis during development. Consistent with
92 this notion, pan-retinal NMNAT1 deletion is shown to cause rapid and severe retinal
93 degeneration in mice shortly after birth (Wang et al., 2017; Eblimit et al., 2018). While these
94 studies suggest diverse functions of retinal NMNAT1 beyond its canonical role in redox
95 metabolism, the degree to which these functions overlap—as well as the mechanistic basis for
96 the severity of NMNAT1-associated retinal dystrophy in animal models and patients—have not
97 been comprehensively explored.

98

99 In this study, we investigate the roles of NMNAT1-mediated NAD⁺ metabolism in the retina by
100 generating and characterizing a retina-specific NMNAT1 knockout mouse model. Utilizing
101 histological and transcriptomic approaches, we demonstrate that NMNAT1 deletion causes
102 severe and progressive retinal degeneration affecting specific retinal cell types beyond
103 photoreceptors, and that this severe degeneration likely results from activation of multiple
104 distinct cell death pathways. Comprehensive metabolomics analysis reveals specific metabolic
105 defects in NMNAT1 knockout retinas and suggests impaired central carbon, purine nucleotide,
106 and amino acid metabolism as a cause for severe degeneration. Furthermore, concomitant
107 transcriptomics analyses of knockout retinas reveal a cluster of photoreceptor and synapse-
108 specific genes which are downregulated before the onset of degeneration, suggesting a yet-
109 undescribed role for NMNAT1 in gene regulation during late-stage retinal development. Overall,
110 our results reveal a previously unappreciated complexity in NMNAT1-associated retinal
111 degeneration, provide possible explanations for the retina-specific manifestations of NMNAT1
112 deficiency, and lay the foundation for further study of compartmentalized NAD⁺ metabolism in
113 vision.


114 **RESULTS**

115

116 **Generation and validation of NMNAT1 conditional knockout mouse model**

117

118 To establish a retinal-specific NMNAT1 knockout model, we crossed mice homozygous for a
119 loxP-targeted *Nmnat1* locus (*Nmnat1^{fl/fl}*) with transgenic mice expressing Cre recombinase under
120 a *Six3* promoter (*Nmnat1^{wt/wt} Six3-Cre*), which activates throughout the retina around embryonic
121 day 9.5 (E9.5) and shows robust activity by E12.5 (Furuta et al., 2000). After several crosses,
122 mice inheriting *Six3-Cre* and a floxed *Nmnat1* locus (*Nmnat1^{fl/fl} Six3-Cre*, hereafter referred to as
123 “knockouts”) exhibit Cre-mediated excision of the first two exons of *Nmnat1*—which contain
124 important substrate binding domains—in the embryonic retina (**Figure 1A**). We determined that
125 retinal *Nmnat1* expression in postnatal day 4 (P4) knockout mice was reduced by 75.6%
126 compared to littermate controls (**Figure 1B**). We further verified that retinal NMNAT1 protein
127 levels were drastically reduced in P0 knockout mice using a custom-made polyclonal antibody
128 against NMNAT1 (**Figure 1C** and **Figure 1—Supplement 1**). Finally, we confirmed that
129 embryonic *Six3-Cre* expression alone does not cause gross retinal abnormalities by staining for
130 several well-characterized cell type markers in mature *Nmnat1^{wt/wt} Six3-Cre* retinas and
131 littermate controls (**Figure 2—Supplement 1**; markers discussed below).



132

133 **Figure 1. Loss of NMNAT1 leads to early and severe retinal degeneration.** (A) Schematic
 134 depicting retina specific *Six3-Cre* mediated excision of a segment of the *Nmnat1* gene. (B)
 135 Relative *Nmnat1* expression in retina from P4 knockout (-/-) and littermate control (+/+) mice as
 136 assessed by RT-qPCR (grey bars represent mean, ***p<0.0005 using Student's t-test, n=3
 137 biological replicates). (C) Representative western blot showing levels of NMNAT1 and β -
 138 tubulin loading control in retinal lysate from P0 knockout and control mice. (D-G)
 139 Representative H&E-stained retinal cross sections from knockout and control mice at indicated
 140 ages. (H-J) Spider plots depicting mean retinal thickness at P0, P4, and P10. Data are
 141 represented as mean \pm SD. *p<0.05 using Student's t-test. Abbreviations: LP, loxP site; E1-4,
 142 exon 1-4; P, postnatal day; GCL, ganglion cell layer; NBL, neuroblastic layer; IPL, inner
 143 plexiform layer; OPL, outer plexiform layer; INL, inner nuclear layer; ONL, outer nuclear layer;
 144 IS/OS, photoreceptor inner segment/outer segment layer.

145

146

147

148

149

150

151 **Early-onset and severe morphological defects in the NMNAT1-null retina**

152

153 As a first step towards characterizing the effects of NMNAT1 ablation on the retina, we
154 performed retinal histology using hematoxylin and eosin (H&E) staining. H&E-stained retinal
155 cross sections from P0 knockout and control mice reveal no obvious morphological differences
156 (**Figure 1D, H**); however, by P4, knockout retina are markedly thinner than controls and exhibit
157 disrupted lamination and evidence of large-scale cell death in the inner and outer nuclear layers
158 (**Figure 1E**). Degeneration is most severe in the central retina, with a ~45% reduction in central
159 retinal thickness (but unaffected peripheral retinal thickness) in P4 knockout mice (**Figure 1I**).
160 By P10, knockouts show a ~62% reduction in central retinal thickness and ~27% reduction in
161 peripheral retinal thickness compared to controls (**Figure 1J**). Degeneration of the entire inner
162 and outer nuclear layers is nearly complete by P30 (**Figure 1G**), while remaining inner retinal
163 structures persist until approximately P60 (data not shown). Proper segregation of inner and
164 outer retinal neurons appears disrupted in P4 knockouts, but this segregation is established in
165 P10 knockouts despite severe degeneration (**Figure 1F**). Interestingly, formation of the outer
166 plexiform layer (containing photoreceptor and bipolar neuron synaptic structures) appears
167 disrupted in P4 and P10 knockout retinas (**Figure 1E, F**).


168

169 **NMNAT1 loss affects survival of retinal bipolar and amacrine neurons**

170

171 Histological examination suggests severe photoreceptor degeneration in NMNAT1 knockout
172 retinas but also indicates loss of specific inner retinal neuron populations. To further characterize
173 these effects, we quantified populations of several major inner retinal cell types in our knockout

174 by staining retinal sections with well-characterized antibody markers: retinal ganglion cells were
175 identified by labelling for brain-specific homeobox/POU domain protein 3A (BRN3A), amacrine
176 cells by labelling for calretinin (CALR), and bipolar cells by labelling for Ceh-10 homeodomain-
177 containing homolog (CHX10) (**Supplemental Table 2**). We performed this analysis at P4 and
178 P10—representing early and late stages of degeneration, respectively—revealing an interesting
179 cell type-dependent sensitivity to NMNAT1 loss (**Figure 2**). At both tested ages, relative
180 numbers of retinal ganglion cells are not significantly different between knockout and control
181 retina (**Figure 2B-E, P**), while numbers of amacrine cells are unchanged at P4 but reduced by
182 ~51% in P10 knockout retinas (**Figure 2G-J, Q**). Numbers of bipolar cells are similarly
183 unchanged at P4 but reduced by ~75% in P10 knockout retinas (**Figure 2L-O, R**). These results
184 identify retinal bipolar and amacrine neurons as targets of NMNAT1-associated degeneration
185 and suggest that bipolar neurons are more sensitive to NMNAT1 loss than amacrine neurons.
186 Interestingly, while retinal ganglion cells do eventually degenerate at timepoints past P30 (data
187 not shown), they appear largely agnostic to NMNAT1 loss in the young postnatal retina.



188
189

190 **Figure 2. NMNAT1 loss affects survival of retinal bipolar and amacrine cells.**
 191 Representative retinal sections from knockout (-/-) and floxed littermate control (+/+) mice at the
 192 indicated ages labelled with antibodies against BRN3A (B-E), Calretinin (CALR) (G-J), and
 193 CHX10 (L-O). Schematics in (A), (F), and (K) depict retinal neuron subtypes labelled by each
 194 respective antibody. Quantification of BRN3A- (P), CALR- (Q), and CHX10-positive cells (R)
 195 are shown. In (Q), only CALR-positive cells on the outer side of the IPL (layer indicated by
 196 arrowheads) were counted. Data is represented as mean \pm SD. n=3 biological replicates for all
 197 panels; significance determined using Student's t-test. Scale bars, 30 μ m.

198 **Loss of NMNAT1 impairs photoreceptor gene expression and severely perturbs early**
199 **postnatal photoreceptor survival**

200

201 Turning our attention to photoreceptors, we repeated the above approach with antibodies against
202 the photoreceptor markers recoverin (anti-RCVRN) and rhodopsin (anti-RHO). While anti-
203 RCVRN cleanly labels developing photoreceptor somas in P4 and P10 control retinas (**Figure**
204 **3B, Figure 3—Supplement 1, panel D**), we observe a complete lack of recoverin expression in
205 knockout retinas at both ages (**Figure 3C, Figure 3—Supplement 1, panel E**). Barring a small
206 amount of non-specific staining likely originating from the secondary antibody (**Figure 3—**
207 **Supplement 1, panels A, B**), rhodopsin expression at P4 and P10 showed an identical trend to
208 that of recoverin (**Figure 3D, E, Figure 3—Supplement 1, panels H,I**).

209

210 Intrigued by the magnitude of recoverin and rhodopsin loss and hypothesizing defects in the
211 expression of other retinal proteins in our knockout, we comprehensively profiled the
212 transcriptomes of knockout and control retinas at two timepoints— pre-degeneration (E18.5) and
213 during degeneration (P4) and using RNA-sequencing. At P4, this analysis reveals 2,976
214 differentially-expressed genes in NMNAT1 knockout retinas (**Figure 3—Supplement 2, panel**
215 **B**), several of which we validated using RT-qPCR (**Figure 3—Supplement 1, panel C**).

216 Consistent with the lack of recoverin and rhodopsin staining at this age, gene set enrichment
217 analysis (GSEA) of P4 differentially-expressed genes (DEGs) reveals several large, highly-
218 overrepresented clusters of downregulated photoreceptor-related genes including both recoverin
219 and rhodopsin (**Figure 3—Supplement 2, panel C**). Strikingly, among 815 DEGs in E18.5
220 knockout retinas, a similar cluster of downregulated genes associated with visual perception and

221 the photoreceptor outer segment was observed (**Figure 3—Supplement 3, panels B, C**).

222 Combining both RNA-sequencing datasets reveals a group of 365 DEGs in knockout retinas

223 common to both timepoints (**Figure 3F**). Importantly, GSEA on this gene set reveals highly-

224 overrepresented clusters of photoreceptor and synapse associated genes (**Figure 3G**), and further

225 analysis identifies a core set of 21 photoreceptor-associated genes which are significantly

226 downregulated in E18.5 and P4 NMNAT1 knockout retinas (**Figure 3H, I**). Notably, this set

227 includes rod-specific (e.g. *Gngt1*), cone-specific (e.g. *Opn1sw*, *Cnga3*) and photoreceptor-

228 specific (e.g. *Prph2*, *Rcvrn*, *Aipl1*) genes of diverse function, many of which have important

229 roles in photoreceptor development and function. Consistent with a specific transcriptional effect

230 on photoreceptors, we confirmed that expression of several well-known ganglion cell,

231 amacrine/horizontal cell, and bipolar cell specific genes was largely unchanged in NMNAT1

232 knockout retinas at either tested age (**Figure 3—Supplement 4**). Altogether, these results

233 implicate NMNAT1 in gene regulation during late-stage retinal development, suggests

234 photoreceptor-specific transcriptional dysregulation as a driver of the severe photoreceptor

235 phenotype in NMNAT1 deficient retinas.

236


237 Beyond affecting photoreceptor-specific gene expression, we also note downregulation of 6

238 synapse-associated genes (*Stx3*, *Syngr1*, *Cln3*, *Scamp5*, and *Sv2b*) in both E18.5 and P4 knockout

239 retinas (**Figure 3—Supplement 5, panels C, D**), consistent with disruptions to outer plexiform

240 layer formation in P4 knockout retinas on histology and on staining with the synapse marker

241 synaptophysin (anti-SYPH) (**Figure 3—Supplement 5**).



242
243
244

245 **Figure 3. NMNAT1 loss severely affects early postnatal photoreceptor gene expression and**
246 **survival.** Representative retinal sections from knockout (-/-) and floxed littermate control (+/+) **(B-C)**
247 mice at the indicated ages labelled with antibodies against recoverin (RCVRN) **(B-C)** or
248 rhodopsin (RHO) **(D-E)**. Schematic in **(A)** depicts retinal neuron subtypes labelled by the
249 recoverin and rhodopsin antibodies. **(F)** Comparison of differentially-expressed genes in E18.5
250 and P4 knockout retinas as assessed by RNA-sequencing. **(G)** GSEA of differentially-expressed
251 genes present in E18.5 and P4 knockout retinas. **(H, I)** Relative expression of indicated genes in
252 P4 and E18.5 knockout retinas as assessed by RNA-sequencing. n=3 biological replicates for **(B-**
253 **E)**, n=5 biological replicates for **(H)**, n=3 biological replicates for **(I)**. Corresponding zoom
254 panels are indicated with dotted rectangles. Scale bars, 30 μ m.
255

256 **Loss of NMNAT1 during retinal development triggers multiple cell death pathways**

257

258 As NMNAT1 deficiency drastically impairs the postnatal survival of photoreceptor, bipolar, and
259 amacrine retinal neurons, we sought to determine the mechanisms by which these cells

260 degenerate. To this aim, we began by staining retinal sections with an antibody against activated

261 caspase-3 (AC3). While P0 knockout retinas show little AC3 staining compared to controls—

262 consistent with grossly normal retinal morphology at this age—P4 knockout retinas show robust

263 AC3 immunoreactivity in the inner and outer nuclear layers (**Figure 4A-D**). As expected, most

264 AC3-immunoreactive (AC3⁺) cells display nuclear chromatin condensation ('pyknosis')

265 characteristic of dying cells; however, staining also reveals a population of pyknotic nuclei not

266 immunoreactive to AC3 (AC3⁻) (**Figure 4A'-D', arrows**). Interestingly, these pyknotic, AC3⁻

267 nuclei were sparsely present in P0 and P4 control retinas (**Figure 4A,C**) and to a larger extent in

268 P0 and P4 knockout retinas (**Figure 4B,D**). Quantification (**Figure 4E**) reveals a general trend of

269 cell death consistent with our histology and cell-marker investigations: nuclear pyknosis is

270 slightly elevated in P0 knockout retinas compared to controls, peaks at P4 where we observe

271 robust retinal degeneration, and is virtually absent by P10, by which time the majority of outer


272 and inner nuclei in the knockout are lost (**Figure 1D**). Interestingly, we observe roughly equal

273 amounts of AC3⁺ and AC3⁻ pyknotic cells in P0 knockout retinas, whereas by P4 AC3⁻ pyknotic

274 cells constitute ~30% of pyknotic cells in knockout retinas (**Figure 4E**). In addition to being

275 present at all tested ages and following the same general trend as AC3⁺

276



277
278

279 **Figure 4. NMNAT1 loss causes activation of multiple cell death pathways in the retina. (A-**
 280 **D)** Representative retinal sections from knockout (-/-) and floxed littermate control (+/+) mice at
 281 the indicated ages labelled with an antibody against active Caspase-3 (AC3). Corresponding
 282 zoom panels are indicated with dotted rectangles. Arrows denote pyknotic, AC3-negative nuclei.
 283 **(E)** Quantification of pyknotic nuclei in sections from knockout and control mice at the indicated
 284 ages, grouped by presence (AC3+) or absence (AC3-) of active Caspase-3 labeling. Relative
 285 expression of several apoptotic **(F)**, pyroptotic **(G)**, and necroptotic **(H)** genes in P4 knockout
 286 retinas as assessed by RNA-sequencing. **(I)** Relative expression of *Sarm1* in P4 knockout and
 287 control retinas as assessed by RNA-sequencing. **(J)** Relative abundance of cyclic-ADP-ribose
 288 (cADPR) in P4 knockout and control retinas as measured by mass spectrometry (grey bars
 289 represent means). Data are represented as mean \pm SD. Significance determined using Tukey's
 290 multiple comparisons test for **(E)**, DESeq2 for **(F-I)** (see methods), or Student's t-test for **(J)**.
 291 n=3 biological replicates per condition for **(A-E)**, n=5 biological replicates for **(F-I)**, n=6
 292 biological replicates (one outlier removed) for **(J)**. Scale bars, 30 μ m.
 293

294 pyknotic cells, AC3⁻ pyknotic cells often appear in distinct clusters (**Figure 4D'**), distinguishable
295 from the more evenly dispersed AC3⁺ pyknotic cells. These results suggest the activation of at
296 least two distinct cell death pathways in NMNAT1 knockout retinas between P0 and P4.

297

298 To more comprehensively characterize NMNAT1-associated cell death and identify possible
299 caspase 3-independent cell death pathways in our knockout, we leveraged the E18.5 and P4
300 RNA-sequencing datasets mentioned above. This allowed us to systematically assay the
301 expression of a collection of genes associated with several major cell death pathways (**Figure**
302 **4—Supplement 2**). Consistent with AC3 staining, we observe deregulation of a collection of
303 apoptosis-related genes in P4 knockout retina, including significant increases in *Noxa* and *Fas*,
304 two pro-apoptotic genes previously associated with cell death in NMNAT1-deficient retinas
305 (Kuribayashi et al., 2018) (**Figure 4F**). Notably, two of these genes—*Noxa* and *Chop*—are also
306 significantly deregulated at E18.5, prior to significant retinal degeneration (**Figure 4—**
307 **Supplement 1, panel A**).

308

309 In addition to transcriptional signatures of apoptosis, we identified upregulation of a collection of
310 genes associated with pyroptosis in P4 NMNAT1 knockout retinas (**Figure 4G**). Pyroptosis is
311 characterized by assembly of a multi-protein complex called the ‘inflammasome,’ which
312 ultimately cleaves and activates the pore-forming members of the gasdermin family of proteins
313 to elicit lytic cell death in response to a variety of perturbations (McKenzie et al., 2020).
314 Interestingly, we find upregulation of all three classical inflammasome components—*Nlrp3*,
315 *Casp1*, and *Pycard* (ASC)—in P4 knockout retinas (**Figure 4G**), with *Nlrp3* upregulation at
316 E18.5 as well (**Figure 4—supplement 1, panel B**). In addition, we observe significant increases

317 in *Irf2*, a transcriptional activator of gasdermin D (Kayagaki et al., 2019), as well as pyroptosis-
318 associated proteins *Ripk1* and *Tlr2* at P4 (**Figure 4G**). Notably, expression of *Tlr2* and related
319 protein *Tlr4* is significantly elevated in E18.5 knockout retinas (**Figure 4—Supplement 1, panel**
320 **B**). Finally, we also observed dysregulation of several genes associated with necroptosis (**Figure**
321 **4H**) and ferroptosis (**Figure 4—Supplement 2, panel D**) in P4 knockout retinas; while none of
322 these genes were significantly upregulated at E18.5, we do observe an early induction of
323 necroptosis-associated protein *Nox2* at this age (**Figure 4—Supplement 1, panel C**).

324
325 Recently, photoreceptor cell death in a postnatally-induced global NMNAT1 knockout mouse
326 was shown to depend heavily on the activity of the pro-degenerative axonal protein SARM1
327 (Sasaki et al., 2020a). Reasoning SARM1 as the culprit behind the caspase 3-independent cell
328 death in our model, we checked *Sarm1* expression in our RNA-seq data and assayed SARM1
329 activity by measuring levels of its catalytic product cyclic ADP-ribose (cADPR) using targeted
330 mass spectrometry in P4 and E18.5 NMNAT1 knockout and control retinas. Surprisingly, we
331 found no significant changes in SARM1 expression (**Figure 4I, Figure 4—Supplement 1, panel**
332 **D**) or activity (**Figure 4J, Figure 4—Supplement 1, panel E**) at either tested age. Overall, these
333 data reveal that activation of multiple cell death pathways underlies the early and severe
334 degeneration observed in NMNAT1 knockout retinas, and suggest pyroptosis and apoptosis as
335 drivers of this degeneration.

336

337

338 **Global metabolic alterations in NMNAT1 deficient retinas**

339

340 To identify possible mechanisms for the severe and cell type-specific retinal degeneration in our
341 model, we next sought to characterize global metabolic consequences of embryonic NMNAT1
342 deletion in the retina. To this end, we used targeted liquid chromatography-tandem mass
343 spectrometry (LC-MS/MS) to quantify levels of ~112 cellular metabolites spanning many
344 essential biochemical pathways in NMNAT1 knockout and control retinas at pre- and post-
345 degenerative timepoints matching that of our RNA-sequencing analyses (E18.5 and P4). While
346 LC-MS/MS analysis reveals no significant changes in E18.5 knockout retinas compared to
347 controls, analysis at P4 reveals significantly altered levels of 39 metabolites in knockout retinas
348 (**Figure 5, Figure 5—Supplement 1**). Metabolite set enrichment analysis (MSEA) identifies
349 potential disruption of several diverse biochemical pathways including amino acid metabolism,
350 glycolysis/gluconeogenesis, nicotinate and nicotinamide metabolism, and purine metabolism
351 (**Figure 5B**).

352

353 NMNAT1 knockout retinas show specific metabolic disruptions to NAD⁺ biosynthesis pathways.
354 At P4, knockouts show a ~40% reduction of total retinal NAD⁺ levels and levels of nicotinic acid
355 adenine dinucleotide (NaAD), the other catalytic product of NMNAT1 (**Figure 5C, D**). Levels of
356 the downstream metabolites NADP and nicotinamide (NAM) were decreased by ~25% and
357 ~55%, respectively, while levels of NADH were slightly decreased ($p > 0.05$) (**Figure 5C**). As
358 expected, we observe significant accumulation of NAD precursors nicotinamide riboside (NR)
359 and nicotinamide mononucleotide (NMN) in P4 knockout retinas (**Figure 5C**); however, we

360 observe no significant changes in levels of tryptophan, the starting point for de novo NAD
361 synthesis, at this age (**Figure 5C, D**).

362

363 **Retinal NMNAT1 loss causes disruption of central carbon metabolism**

364

365 Interestingly, the set of significantly altered metabolites in P4 knockout retinas is enriched for
366 metabolites associated with glycolysis, gluconeogenesis, and the Warburg effect (**Figure 5B**).

367 Closer examination of these pathways reveals large relative increases in levels of the upstream

368 glycolytic metabolites glucose, glucose 6-phosphate (G6P) and fructose 1,6-bisphosphate

369 (F16BP), as well as significant decreases in levels of dihydroxyacetone phosphate (DHAP) and

370 glucose 3-phosphate (G3P) (**Figure 5E, F**), strongly suggesting a disruption to glucose

371 utilization. Consistent with such an effect, levels of the TCA cycle intermediates alpha-

372 ketoglutarate (a-KG) and succinate are decreased by ~30% in P4 knockout retinas (**Figure 5E,**

373 **F**). Further in line with disruptions to downstream mitochondrial metabolism, we observe







374 reduction of several acylcarnitine species at this age as well (**Figure 5—Supplement 1, panel**

375 **A**). Although we observe decreased levels of the ATP-recycling metabolites phosphocreatine and

376 creatine at P4, retinal ATP levels at this age are slightly but not significantly reduced ($p = 0.5$)

377 (**Figure 5F**).

378



380 **Figure 5. Loss of NMNAT1 impairs retinal central carbon metabolism.** (A) Schematic
381 illustrating metabolomics experimental approach. (B) Results of metabolite set enrichment
382 analysis (MSEA) on significantly changed metabolites in P4 knockout retinas. (C) Relative
383 abundance of NAD⁺ pathway metabolites in P4 knockout retinas as assessed by mass
384 spectrometry. (D) Schematic illustrating the major mammalian NAD⁺ synthesis pathways
385 colored according to metabolite changes in (C); NMNAT1-catalyzed steps are indicated with
386 asterisks. (E) Relative abundance of glycolysis, TCA cycle, and creatine metabolites in P4
387 knockout retinas as assessed by mass spectrometry. (F) Schematic depicting abbreviated
388 glycolysis/TCA cycle pathway colored according to metabolite changes in (E); aldolase-
389 catalyzed step is indicated by a single asterisk, while GAPDH-catalyzed step is marked with a
390 double asterisk. (G) Heatmap of log-transformed relative expression of a set of glycolysis/TCA
391 cycle genes in P4 knockout (-/-) and control retinas (+/+) as assessed by RNA-sequencing. (H)
392 Relative abundance of pentose-phosphate pathway (PPP) metabolites in P4 knockout retinas as
393 assessed by mass spectrometry. Data are represented as mean ± SD. n=6 biological replicates for
394 (B,C,E,H), n=5 biological replicates for (G).
395

396 To further investigate possible glycolytic disruptions in P4 knockout retinas, we assayed the
397 expression of a collection of glycolysis and TCA cycle enzymes in P4 knockout and control
398 retinas using our RNA-sequencing dataset. Indeed, this analysis reveals broad transcriptional
399 changes in 16 glycolytic and 4 TCA cycle enzymes in P4 knockout retinas (**Figure 5G**).
400 Notably, two of these changes—upregulation of the aldehyde dehydrogenase *Aldh8a1* and
401 downregulation of the TCA cycle enzyme *Ogdhl*—are also present in RNA-sequencing results
402 from the pre-degenerative (E18.5) timepoint (**Figure 5—Supplement 1, panel B**). Finally,
403 consistent with disruption of glycolytic flux and reduced NADP levels in knockout retinas, mass
404 spectrometry suggests possible disruption of the pentose phosphate pathway (PPP) evidenced by
405 decreased levels of erythritol at this age (**Figure 5H**).

406

407 **NMNAT1 loss disrupts retinal purine metabolism and a subset of amino acids**

408

409 As MSEA also indicated possible disruptions of purine metabolism and several amino acid
410 pathways in P4 NMNAT1 knockout retinas (**Figure 5B**), we closely examined levels of a
411 collection of metabolites representing most major nucleotide and amino acid metabolites in P4
412 knockout and control retinas (**Figure 5—Supplement 2**). Interestingly, while levels of the
413 pyrimidine nucleotide derivatives uracil, UDP, and cytidine were unchanged at this age, levels of
414 the purine nucleotide precursor xanthine, guanine, and GMP were increased by ~150%, ~147%,
415 and ~58%, respectively (**Figure 5—Supplement 2, panel A**). The sole affected pyrimidine
416 nucleotide was cytosine, which showed an impressive ~352% increase in P4 knockout retinas as
417 compared to controls (**Figure 5—Supplement 2, panel A**). In addition to defects in purine
418 metabolism, we observe significant changes in a subset of 10 amino acids and amino acid

419 derivatives in P4 knockout retinas including acetyl-asparagine and acetyl-lysine (**Figure 5—**
420 **Supplement 2, panel B**).

421

422 Overall, these metabolomics results suggest specific disruptions to central carbon, purine
423 nucleotide, and amino acid metabolism as potential causes for severe retinal degeneration in the
424 absence of NMNAT1.

425

426 **DISCUSSION**

427

428 **NMNAT1-deficiency is associated with early and severe retinal degeneration involving**
429 **multiple cell types**

430

431 In this study, we demonstrate that retinal NMNAT1 deficiency in mice leads to severe
432 degeneration of photoreceptor, bipolar, and amacrine neurons soon after birth. In general, this
433 phenotype is consistent with several recent studies reporting partial or complete ablation of
434 retinal NMNAT1, which report retinal degeneration beginning within the first postnatal week
435 and largely complete by one month of age (Wang, et al., 2017; Eblimit et al., 2018). While the
436 present study describes a relatively rapid timeline of NMNAT1-associated retinal degeneration,
437 it furthers the characterization of this phenotype in two important ways: first, by assessing the
438 survival of specific retinal neuron subtypes, and second, by systematically examining retinal cell
439 death pathways triggered by NMNAT1 deletion.

440

441 Examination of specific cell types in NMNAT1 knockout retinas reveals that, while
442 photoreceptors are likely the primary targets of NMNAT1-associated pathology, retinal bipolar
443 and amacrine cells are also sequentially and significantly affected by loss of NMNAT1 during
444 retinal development, while ganglion cells appear unaffected until later stages. Interestingly, this
445 differential sensitivity is mirrored in our transcriptomics analyses, which demonstrate robust
446 deregulation of a cluster of photoreceptor and several bipolar cell-specific genes but relatively
447 few changes in amacrine or ganglion specific genes. These results stand partially in contrast to a
448 recent study reporting *ex vivo* knockdown of *Nmnat1* in retinal explant cultures, which reported
449 thinner INLs but no changes in numbers of HuC/D-expressing amacrine cells or PKCa-
450 expressing bipolar cells in NMNAT1-deficient explants (Kuribayashi et al., 2018). However, this
451 study did report reduced numbers of PNR-positive photoreceptor cells in NMNAT1-deficient
452 explants, and we believe that differences regarding amacrine and bipolar cell effects can be
453 explained by the fact that *Nmnat1* expression in explants was knocked down relatively late in
454 development (E17.5) as compared to the E9.5 activation of *Six3-Cre* (Furuta et al, 2000).

455
456 While we were unable to successfully determine retinal NMNAT1 distribution using our
457 polyclonal NMNAT1 antibody, previously published results showing RT-qPCR of *Nmnat* levels
458 in flow-sorted rod photoreceptors suggest that NMNAT1 is the predominantly expressed
459 NMNAT isoform in rod photoreceptors (Kuribayashi et al., 2018). Combined with our data
460 confirming a lack of transcriptional upregulation of either *Nmnat2* or *Nmnat3* in NMNAT1
461 knockout retinas (**Figure 3—Supplement 1**), one possible explanation for the cell-type specific
462 degeneration we observe is that relatively higher levels of NMNAT2/3 in inner retinal neurons
463 can partially compensate for the NAD⁺ deficit caused by loss of NMNAT1. Overall, our results

464 demonstrate that NMNAT1 is crucial for the early survival of photoreceptors, bipolar cells, and
465 amacrine cells and suggest retinal cell-type specific requirements of NAD⁺ metabolism.

466

467 **NMNAT1-deficient retinas activate multiple cell death pathways**

468

469 Previous reports of cell death in NMNAT1-deficient retinas center on two potentially contrasting
470 mechanisms: the aforementioned *ex vivo* study outlined a role for *Noxa* and *Fas*-associated,
471 caspase-3 dependent apoptosis in NMNAT1-deficient explants (Kuribayashi et al., 2018), while
472 a recent study found the death of mature photoreceptors after global NMNAT1 deletion to be
473 solely dependent on the neuronal NADase SARM1 (Sasaki et al., 2020a). Using histological and
474 comprehensive transcriptomic approaches, we demonstrate involvement of caspase-3 associated
475 apoptosis in NMNAT1 knockout retinas characterized by an early and sustained upregulation of
476 *Noxa* and deregulation of several other apoptosis-pathway genes. We extend these results by
477 showing histological evidence of a distinct, caspase-3 independent cell death pathway which
478 constitutes a significant portion of observed cell death and closely follows caspase-3 dependent
479 apoptosis throughout the timepoints tested in our model.

480

481 Interestingly, using a recently validated metabolic marker of SARM1 activity (cADPR) (Sasaki
482 et al., 2020b), we do not detect SARM1 involvement at pre- or post-degenerative timepoints in
483 our model. That we do not find evidence of SARM1 involvement, even in the presence of
484 increased levels of its potent activator NMN (Zhao et al., 2019; Figley et al., 2021) is unexpected
485 but not implausible, especially considering the fact that the report implicating SARM1 in
486 NMNAT1-associated degeneration deleted NMNAT1 in mature mice (Sasaki et al., 2020a).

487 Indeed, many apoptosis effectors (*Casp3*, *Casp9*, *Apaf1*, *Bcl* family members) active in the
488 developing mammalian retina are subsequently downregulated in mature retinas, necessitating
489 alternative death pathways for handling pathological insults at these ages (Donovan and Cotter
490 2002; Doonan et al., 2003; Donovan et al., 2006). Considering these results, it is wholly possible
491 that in mature retinas with insufficient expression of necessary apoptotic and/or pyroptotic
492 machinery, NMNAT1-associated retinal degeneration proceeds through SARM1—in such a
493 case, it is important to note that model systems with embryonic or germline deletion or mutation
494 of NMNAT1 are typically more representative of patients with disease-linked mutations in
495 NMNAT1. On the other hand, it cannot be conclusively ruled out that excess cADPR produced
496 by an active SARM1 in our model is rapidly metabolized, and recently described links between
497 SARM1 and both pyroptosis and apoptosis (Mukherjee et al., 2015; Carty et al., 2019) leave
498 open the possibility of cooperation between these cell death pathways in NMNAT1 knockout
499 retinas.

500

501 Our transcriptomics results indicate dysregulation of several pyroptosis and necroptosis-related
502 genes, notably including the entire “canonical inflammasome” (*Casp1*, *Nlrp3*, and *Pycard*), as
503 well as the toll-like receptors *Tlr2* and *Tlr4*, at both timepoints (**Figure 4**). The distinct presence
504 of nuclear pyknosis in AC3⁻ dying cells—which is generally incompatible with necroptosis but
505 documented in pyroptotic cells (Vandenabeele et al., 2010; Murakami et al., 2012; Miao et al.,
506 2011)—lends support to pyroptosis as a significant driver of cell death in NMNAT1-deficient
507 retinas. Intriguingly, we do not detect proteolytic cleavage of gasdermin D—a common marker
508 of pyroptosis—in P4 NMNAT1 knockout retinas (**Figure 4—Supplement 1**). However, recent
509 results indicate that NLRP3 is, under certain circumstances, capable of being activated

510 independently of gasdermin D (Gutierrez et al., 2017). Considering a recent report suggesting
511 involvement of the PARP1-associated ‘parthanatos’ cell death pathway in NMNAT1 mutant
512 retinas (Greenwald et al., 2021), we did not detect accumulation of poly ADP-ribose (PAR) in
513 AC3⁻ pyknotic nuclei (data not shown), arguing against involvement of this pathway under
514 these conditions.

515

516 In sum, we show that retinal NMNAT1 loss activates multiple cell death pathways, which
517 contextualizes the degeneration of multiple cells types in our model and may explain the severity
518 of NMNAT1-associated retinal degeneration in this study and others. Although the model
519 presented here differs in important ways from NMNAT1-mutant LCA animal models, it does
520 recapitulate some aspects of NMNAT1-linked LCA including particularly severe central retinal
521 defects (Kumaran et al., 2017). As recent studies have discovered noncoding mutations, copy
522 number variations, and exon duplications in NMNAT1 causing severe reduction of NMNAT1
523 expression in patients with ocular and extra-ocular pathologies (Coppieters et al., 2015; Bedoni
524 et al., 2020), understanding the mechanisms of retinal degeneration in an NMNAT1 knockout
525 model is of potential clinical significance.

526

527 **Retinal NMNAT1 loss causes diverse metabolic disruptions**

528

529 Several recent studies examine levels of select metabolites in mature NMNAT1-deficient retinas
530 (Sasaki et al., 2020a), or more broadly examine tissue metabolomes after perturbation of the
531 NMN-synthesizing enzyme NAMPT (Lin et al., 2016; Oakey et al., 2019; Lundt et al., 2021).
532 Our metabolomics results approximate that NMNAT1 synthesizes ~40% of the total retinal

533 NAD⁺ pool, which is generally consistent with a previous model (Sasaki et al., 2020a). In
534 addition, our results strongly suggest that—via specific disruptions to central carbon, nucleotide,
535 and amino acid metabolism—depletion of NAD⁺ synthesized in the nucleus disrupts multiple
536 non-nuclear metabolic pathways in the retina. Whether these observations reflect a direct export
537 of nuclear NAD⁺ to cytosolic and mitochondrial retinal compartments versus an indirect effect
538 on cytosolic and mitochondrial cellular processes (by way of NAD⁺-dependent gene regulation,
539 for instance) is a topic for further study.

540

541 Impaired glycolytic flux appears to be a more general feature of tissue NAD⁺ depletion, as
542 studies reporting NAMPT inhibition or deletion in projection neurons and skeletal muscle
543 myotubes report accumulation of glycolytic metabolites upstream of GAPDH (Oakey et al.,
544 2019; Lundt et al., 2021). Interestingly, Lundt et al. present evidence of reversed glycolytic flux
545 in NAMPT-inhibited myotubes, an effect which we believe may explain decreased levels of G3P
546 and DHAP in our model. Notably, unbiased LC-MS/MS and GC-MS analyses of rod-
547 photoreceptor-specific NAMPT knockout retinas showed signatures of mitochondrial metabolic
548 defects—which we observe in our model as well—but detected limited evidence of glycolytic
549 impairment (Lin et al., 2016). This suggests that retinal NMNAT1 and NAMPT depletion,
550 despite both lowering total retinal NAD⁺ levels, produce distinct metabolic phenotypes.

551

552 Retinal neurons—and retinal photoreceptors in particular—are relatively unique in their
553 dependence on aerobic glycolysis (the “Warburg Effect”) during both proliferative and
554 differentiated states (Agathocleous et al., 2012; Ng et al., 2015; Chinchore et al., 2017). Our
555 finding that retinal NMNAT1 loss is detrimental to glycolysis thus offers a potential explanation

556 for the cell type-specific degeneration which we observe: in particular, previous results
557 indicating that differentiation induces an increased reliance on mitochondrial OXPHOS relative
558 to glycolysis in the retina (Agathocleous et al., 2012) might explain why ganglion and amacrine
559 cells—which differentiate relatively early—are less sensitive to NMNAT1 loss in our model than
560 the later born bipolar and photoreceptor cells. Indeed, even in mature retinas, glycolytic
561 perturbations specifically affect photoreceptor health and survival (Chinchore et al., 2015; Zhang
562 et al., 2020; Sinha et al., 2021). Furthermore, recent results linking glycolytic impairment to
563 NLRP3 activation (Sanman et al., 2016) provide a potential explanation of non-apoptotic cell
564 death which we observe in NMNAT1 knockout retinas.

565

566 In addition to glycolytic impairment, we detect specific defects in purine nucleotide and amino
567 acid metabolic pathways in NMNAT1 knockout retinas. As a particularly proliferative tissue, the
568 retina is thought to be highly reliant on adequate nucleotide and amino acid pools to support
569 transcription and translation of cell-specific machinery (Etingof 2001; Ng et al., 2015). Some of
570 the metabolic changes which we observe—for instance, accumulation of the purine precursor
571 xanthine and the amino acid aspartate—appear to be more widely associated with NAD⁺
572 insufficiency or retinal degeneration (Du et al., 2014; Lin et al., 2016; Oakey et al., 2019). On the
573 other hand, we also identify a collection of metabolic changes in these pathways which are not
574 reported in NAMPT-deficient retinas (Lin et al., 2016), potentially explaining differences in
575 retinal phenotypes between these two models, to be explored more in future studies.

576

577 **A potential role for NMNAT1 in photoreceptor terminal differentiation**

578

579 The tightly coordinated and stereotypical differentiation of retinal neuron subtypes from a
580 common progenitor pool has been extensively studied—complementing classical birth-dating
581 studies, recent investigations have begun to explore the massive epigenetic regulation necessary
582 for the development of the mammalian retina (Swaroop et al., 2010; Aldiri et al., 2017;
583 Raeisossadati et al., 2021). One of the most surprising findings of the present study is an early
584 and sustained transcriptional downregulation of a subset of photoreceptor- and synapse-specific
585 genes in NMNAT1 knockout retinas. Beyond these transcriptional disruptions, we show near
586 complete absence of rhodopsin and recoverin protein in P4 NMNAT1 knockout retinas. While
587 NMNAT1 has previously been implicated in gene regulation through direct interaction with
588 SIRT1 and PARP1 at gene promoters (Zhang et al., 2012; Song et al., 2013) and NMNAT1
589 knockdown was shown to influence apoptotic gene expression by potentially modulating histone
590 acetylation (Kuribayashi et al., 2018), no *in vivo* role for NMNAT1 in retinal developmental
591 gene regulation has yet been described.

592
593 Photoreceptors are among the last retinal cell types to fully develop and are generated in two
594 broad phases: an early cell-fate commitment mediated by several well-characterized transcription
595 factors including OTX2, NRL, and CRX, and a later phase (“terminal differentiation”)
596 comprising expression of a host of specialized phototransduction genes and growth of light-
597 sensing cellular structures (Swaroop et al., 2010; Brzezinski and Reh, 2015; Daum et al., 2017).
598 Interestingly, we do not observe transcriptional changes in OTX2, NRL, CRX, or related genes
599 in NMNAT1 knockout retinas at either tested age. This fact, combined with grossly normal
600 retinal morphology at P0, suggests that NMNAT1 is required for terminal differentiation but not
601 early specification or proliferation of retinal photoreceptor cells. Increased abundance of acetyl-

602 lysine in knockout retinas on mass spectrometry (**Figure 6B**) and GO enrichment of several
603 genes associated with DNA methylation, epigenetic regulation, and chromatin silencing in P4
604 knockout retinas (**Figure 3—Supplement 2**) support a potential role for NMNAT1 in the
605 epigenetic regulation of photoreceptor terminal differentiation, a phenomenon recently shown to
606 feature genome-wide methylation and acetylation events (Aldiri et al., 2017).

607
608 In conclusion, this study presents the most comprehensive evaluation of NMNAT1-associated
609 retinal dysfunction to date and suggests crucial roles for nuclear NAD⁺ in the proper
610 development and early survival of the mammalian retina. While we provide evidence that the
611 early and severe retinal degeneration associated with NMNAT1 loss involves multiple cell types
612 and death pathways, it appears that this severe phenotype stems from two major problems: 1.)
613 metabolic defects likely caused by insufficient NAD⁺ for retinal proliferative metabolism, and 2.)
614 gene regulation defects potentially caused by insufficient nuclear NAD⁺ in developing
615 photoreceptors. Considering links between metabolic state and differentiation in the retina and
616 recently discovered roles of compartmentalized NAD⁺ in non-retinal cell differentiation
617 (Agathocleous et al., 2012; Agathocleous et al., 2013; Ryu et al., 2018), these two problems
618 may not be mutually exclusive. Further study of NMNAT1-associated retinal dysfunction should
619 focus on evaluating the relative contributions of metabolic and genetic deficits to the overall
620 pathology and testing the hypothesis that NMNAT1 functions to integrate retinal energy
621 metabolism and gene regulation.

622

623 **MATERIALS AND METHODS**

624

625 **Animal Model Generation, Husbandry, and Genotyping**

626 *Nmnat1*^{fl/fl} mice were described previously (Conforti 2011) were thoroughly backcrossed with

627 wild-type 129/SV-E mice (Charles River Laboratories, Wilmington, MA) prior to analyses.

628 Conditional knockout mice were generated by crossing *Nmnat1*^{fl/fl} mice with transgenic mice

629 expressing Cre recombinase under a *Six3* promoter (*Six3-Cre*) (Christiansen et al., 2011).

630 Crosses yielded heterozygous *Nmnat1*^{fl/wt} and *Six3-Cre Nmnat1*^{fl/wt} offspring, which were further

631 crossed with *Nmnat1*^{fl/fl} mice to yield conditional knockout (*Six3-Cre Nmnat1*^{fl/fl}) and littermate

632 control (*Nmnat1*^{fl/fl}) mice at approximately Mendelian ratios. Experimental animals were

633 periodically backcrossed with wild-type 129/SV-E mice to maintain genetic integrity. Animals

634 were maintained under standard 12 hour light/dark cycles with food and water provided *ad*

635 *libitum*. All experimental procedures involving animals were approved by the Institutional

636 Animal Care and Use Committee (IACUC) of West Virginia University.

637

638 Animals were genotyped using polymerase chain reaction (PCR) of genomic DNA from ear

639 punch biopsies. Primer sequences for detection of *Six3-Cre* transgene and *Nmnat1* 5' and 3' loxP

640 sites are listed in **Supplementary Table 1**, and primers were added to the PCR reaction at a final

641 concentration of 0.75 μ M. The thermocycling conditions were 95°C for 2 minutes, 35 cycles of

642 95°C for 30s, 58°C for 30s, 72°C for 45s, and a final extension step of 72°C for 5 minutes.

643

644 **NMNAT1 Antibody Generation**

645 A rabbit polyclonal antibody against amino acids 111-133 of mouse NMNAT1 (sequence

646 CSYPQSSPALEKPGKRKRWADQK) was generated by Pacific Immunology Corp. (Pacific

647 Immunology, Ramona, CA). The affinity-purified antibody was confirmed to recognize

648 NMNAT1 in cell culture and retinal lysate (**Figure 1—Supplement 1**), and did not recognize
649 overexpressed FLAG-NMNAT2 (data not shown).

650

651 **Mammalian Cell Culture and Transfection**

652 HEK293T cells were maintained in 1:1 DMEM/F-12 culture media (Thermo Fisher Scientific,
653 Waltham, MA) in a sterile incubator at 37°C and 5% CO₂. Transient transfection of FLAG-
654 NMNAT1 and FLAG-NMNAT2 constructs (see Supplemental Table 2) was performed at ~60%
655 confluence using TransIT[®]-LT1 transfection reagent (Mirus Bio, Madison, WI) according to
656 manufacturer's instructions. Cells were harvested 48 hours after transfection on ice with 1X
657 Hank's balanced salt solution (HBSS) (Thermo Fisher Scientific) and cell pellets were processed
658 for western blotting as described below.

659

660 **Retinal Histology and Thickness Quantification**

661 To evaluate gross retinal histology, mice at the indicated ages were sacrificed and their eyes were
662 gently removed into 1ml Excalibur's Alcoholic z-fix (Excalibur Pathology Inc., Norman, OK).
663 Subsequent fixation, paraffin embedding, sectioning, and hematoxylin and eosin (H&E) staining
664 were performed by Excalibur Pathology. H&E-stained sections were imaged on a Nikon Eclipse
665 Ti microscope with DS-Ri2 camera (Nikon Instruments, Melville, NY). Retinal thickness was
666 measured using Nikon NIS-Elements software at 4 equidistant points along the outer retinal edge
667 to either side of the optic nerve, where retinal thickness is defined as the length of a line
668 orthogonal to the outer retinal edge and terminating at the inner retinal edge. Thickness was
669 quantified using 6 technical replicates per animal and 3 biological replicates per genotype.

670

671 **Western Blotting**

672 For determination of protein levels by western blot, retinas were homogenized in cold lysis
673 buffer (1X phosphate-buffered saline pH 7.4 (Thermo Fisher Scientific), Pierce[®] protease
674 inhibitor, EDTA-free (Thermo), Calbiochem[®] phosphatase inhibitor cocktail (EMD Biosciences,
675 La Jolla, CA)) using a Microson[®] ultrasonic cell disruptor. Protein concentration was determined
676 using a Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific), after which Laemmli
677 sample buffer was added to a final concentration of 1X (2% SDS, 0.05M Tris-HCl pH 6.8, 10%
678 glycerol, 1% β -mercaptoethanol, 2 mM dithiothreitol (DTT), 0.001% bromphenol blue) and
679 samples were boiled for 5 minutes. Equal amounts of protein were separated on anykD[®] mini-
680 PROTEAN TGX polyacrylamide gels (Bio-Rad, Hercules, CA) and transferred to an
681 Immobilon-FL PVDF membrane (Millipore, Burlington, MA). Membranes were blocked with
682 Odyssey[®] blocking buffer (LI-COR Biosciences, Lincoln, NE) for 1 hour at room temperature
683 and incubated with primary antibodies diluted in 50/50 blocking buffer/1X PBST (1X PBS +
684 0.1% Tween-20) at 4°C overnight on a bidirectional rotator. A list of primary antibodies, sources,
685 and dilutions can be found in **Supplemental Table 2**. Following primary antibody incubations,
686 membranes were washed in 1X PBST and incubated with goat anti-rabbit Alexa Fluor 680
687 and/or goat anti-mouse DyLight 800 secondary antibodies (Thermo Fisher Scientific) for 1 hour
688 at room temperature. Membranes were subsequently washed in 1X PBST and imaged using an
689 Odyssey Infrared Imaging System (LI-COR Biosciences).

690

691 **Quantitative Reverse Transcriptase-PCR (RT-qPCR)**

692 To determine relative gene expression using RT-qPCR, retinas were collected and total RNA
693 was isolated as described below. cDNA was synthesized with a RevertAid[®] cDNA Synthesis Kit

694 (Thermo Fisher Scientific) per manufacturer instructions, starting with 1µg total RNA/sample
695 and using random hexamer primers. Primers for targets of interest were designed using NCBI
696 Primer-BLAST (<https://www.ncbi.nlm.nih.gov/tools/primer-blast/>) to straddle at least one intron
697 of length >500bp. qPCR reactions were performed using Brilliant II SYBR® Green qPCR
698 master mix with low ROX (Agilent Technologies, Cedar Creek, TX) and monitored on a
699 Stratagene® Mx3000P cycler (Agilent Technologies). Prior to use, primers were validated (by
700 examining melt curves and agarose gel electrophoresis) to amplify single products of expected
701 size. Three technical replicates per target per animal were performed, and averages from three
702 animals per genotype are reported. All expression values were normalized to the geometric
703 average of three housekeeping genes (*Hmbs*, *Ppia*, and *Ywhaz*).

704

705 **Immunofluorescent Staining**

706 After euthanasia, eyes were gently removed, punctured, and immersed in 4% paraformaldehyde
707 fixative (4% paraformaldehyde in 1X PBS) (Electron Microscopy Sciences, Hatfield, PA) for 15
708 minutes, after which the cornea was removed and the eye was fixed for an additional 45 minutes
709 at room temperature with gentle agitation. Subsequently, eyes were washed in 1X PBS and
710 incubated in a dehydration solution (20% sucrose in 1X PBS) for at least 12 hours at 4°C. After
711 dehydration, samples were incubated in a 1:1 mixture of 20% sucrose and Tissue-Tek® O.C.T.
712 compound (Sakura Finetek, Torrance, CA) for at least 1 hour before being transferred to 100%
713 O.C.T. and flash frozen. 16 µm sections were cut using a Leica CM1850 cryostat (Leica
714 Biosystems, Nussloch, Germany) and mounted on Superfrost Plus slides (Fisher Scientific). For
715 immunofluorescent staining, retinal sections were briefly rinsed with 1X PBS and incubated in
716 blocking buffer (10% normal goat serum, 0.5% Triton X-100, 0.05% sodium azide in 1X PBS)

717 for 1 hour at room temperature. Following blocking, sections were incubated with the indicated
718 primary antibodies (diluted in buffer containing 5% normal goat serum, 0.5% Triton X-100,
719 0.05% sodium azide in 1X PBS) overnight at 4°C. The next day, sections were washed with 1X
720 PBST and incubated with DAPI nuclear stain (Thermo Fisher Scientific), goat anti-rabbit Alexa
721 Fluor-568 and/or goat anti-mouse Alexa Fluor-488 (Thermo Fisher Scientific) secondary
722 antibodies for 1 hour at room temperature. For antibody information and dilutions, see
723 **Supplemental Table 2**. Finally, sections were washed, cover-slipped with Prolong Gold[®]
724 antifade reagent (Thermo Fisher Scientific), and imaged on a Nikon Eclipse Ti laser scanning
725 confocal microscope with C2 camera (Nikon Instruments). Experimental and control sections
726 were imaged using identical laser intensity and exposure settings. All fluorescent images
727 represent maximum intensity z-projections generated using ImageJ with the Bio-Formats plugin
728 (<https://imagej.net/Bio-Formats>).

729

730 **Retinal Cell Type and Caspase-Positive Cell Quantification**

731 To estimate numbers of pyknotic and caspase-3 positive/negative cells in retinas of knockout and
732 control mice, pyknotic nuclei were manually counted in 212.27 x 212.27 μm^2 regions of
733 maximum intensity projection fluorescent images from the central retina. Once these pyknotic
734 nuclei were identified, the number also labeled with active-Caspase-3 were manually counted.
735 Counts from two technical replicates per animal were averaged, and averages from three animals
736 per genotype are reported. Counts of retinal cell subtypes were estimated by manually counting
737 marker-positive cells in 318.2 x 318.2 μm^2 regions of central retina, averaged between two
738 technical replicates per animal and three animals per genotype. All counts were obtained using
739 ImageJ. For antibody information, see **Supplemental Table 2**.

740

741 **Retinal RNA Extraction, Sequencing, and Analysis**

742 Following euthanasia and eye enucleation, retinae were quickly dissected and transferred into
743 ultra-sterile microcentrifuge tubes containing a small amount of Trizol[®] reagent (Thermo Fisher
744 Scientific), and flash frozen on dry ice. Total RNA was extracted by homogenizing thawed
745 samples with a handheld homogenizer and incubating for 5 min. at room temperature. 20µl
746 chloroform was added to each sample, samples were briefly vortexed, incubated at room
747 temperature for 4 min., and spun at 12,000 rpm for 10 min. at 4°C. The aqueous layers were
748 removed to separate tubes containing 50µl isopropanol and incubated at room temperature for 10
749 min. with occasional agitation. Finally, samples were again spun at 12,000 rpm for 10 min. at
750 4°C, supernatants were removed, and pellets were washed three times with 75% ethanol, dried,
751 and resuspended in DEPC-treated water. Whole-transcriptome sequencing was performed by
752 MacroGen Corp. (MacroGen USA, Rockville, MD) using an Illumina TruSeq Stranded mRNA
753 Library Prep Kit on a NovaSeq6000 S4 to a depth of 100M total reads per sample. Read quality
754 was verified using FastQC (<https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>) and
755 adapters were trimmed using the Bbduk utility of the BBTools package
756 (<http://sourceforge.net/projects/bbmap/>). Read alignment was performed using HISAT2 2.1.0
757 (Kim et al., 2015) and transcripts were assembled and quantified using StringTie 1.3.6 (Pertea et
758 al., 2015; Pertea et al., 2016). Differentially expressed genes were identified using the DESeq2 R
759 package (Love et al., 2014).

760

761 **Targeted Steady-State Metabolomics using LC-MS/MS**

762 Following euthanasia and eye enucleation, retinæ were quickly dissected into Hank's Balanced
763 Salt Solution (HBSS) and flash frozen on liquid nitrogen. Metabolites were extracted according
764 to previously described protocols (Grenell et al., 2019; Yam et al., 2019). Metabolite extracts
765 were analyzed by a Shimadzu LC Nexera X2 UHPLC coupled with a QTRAP 5500 LC-MS/MS
766 (AB Sciex). An ACQUITY UPLC BEH Amide analytic column (2.1x50 mm, 1.7 µm) (Waters
767 Corp., Milford, MA) was used for chromatographic separation. The mobile phase was (A) water
768 with 10 mM ammonium acetate (pH 8.9) and (B) acetonitrile/water (95/5) with 10 mM
769 ammonium acetate (pH 8.2) (All solvents were LC-MS Optima grade from Fisher Scientific).
770 The total run time was 11 min. with a flow rate of 0.5 ml/min. and an injection volume of 5 µl.
771 The gradient elution was 95–61% B in 6 min, 61–44% B at 8 min, 61–27% B at 8.2 min, and 27–
772 95% B at 9 min. The column was equilibrated with 95% B at the end of each run. The source and
773 collision gas was N₂. The ion source conditions in positive and negative mode were: curtain gas
774 (CUR) = 25 psi, collision gas (CAD) = high, ion spray voltage (IS) = 3800/-3800 volts,
775 temperature (TEM) = 500 °C, ion source gas 1 (GS1) = 50 psi, and ion source gas 2 (GS2) = 40
776 psi. Each metabolite was tuned with standards for optimal transitions. D4-nicotinamide
777 (Cambridge Isotope Laboratories, Tewksbury, MA) was used as an internal standard. The
778 extracted MRM peaks were integrated using MultiQuant 3.0.3 software (AB Sciex, Concord,
779 ON, CA).

780

781 **Statistical Analyses**

782 Sample number (n) is defined as number of animals per genotype. Specific statistical tests and
783 sample sizes are indicated in figure legends. Where applicable, p-value adjustments for multiple
784 comparisons were performed and indicated, and reported as 'q' values. Across all figures,

785 statistical significance is defined as $p < 0.05$ (or $q < 0.05$, where applicable). Experimenters were
786 not blinded to treatments.

787

788 **ACKNOWLEDGEMENTS**

789 We thank Dr. Laura Conforti for the *Nmnat1^{fl/fl}* animals, and current and past members of the
790 Kolandaivelu lab for constant support. This work was supported by bridge funding to SK and the
791 National Institutes of Health (RO1EY028959 to SK).

792

793 **COMPETING INTERESTS**

794 The authors declare no competing interests.

795

796 **REFERENCES**

797 Agathocleous, Michalis, and William A. Harris. “Metabolism in Physiological Cell Proliferation
798 and Differentiation.” *Trends in Cell Biology* 23, no. 10 (October 2013): 484–92.

799 <https://doi.org/10.1016/j.tcb.2013.05.004>.

800

801 Aldiri, Issam, Beisi Xu, Lu Wang, Xiang Chen, Daniel Hiler, Lyra Griffiths, Marc Valentine, et
802 al. “The Dynamic Epigenetic Landscape of the Retina During Development, Reprogramming,
803 and Tumorigenesis.” *Neuron* 94, no. 3 (May 2017): 550-568.e10.

804 <https://doi.org/10.1016/j.neuron.2017.04.022>.

805

806 Aleman, Tomas S., Katherine E. Uyhazi, Leona W. Serrano, Vidyullatha Vasireddy, Scott J.
807 Bowman, Michael J. Ammar, Denise J. Pearson, Albert M. Maguire, and Jean Bennett. “RDH12
808 Mutations Cause a Severe Retinal Degeneration With Relatively Spared Rod Function.”
809 *Investigative Ophthalmology & Visual Science* 59, no. 12 (October 1, 2018): 5225.

810 <https://doi.org/10.1167/iovs.18-24708>.

811

812 Bedoni, N., Quinodoz, M., Pinelli, M., Cappuccio, G., Torella, A., Nigro, V., Testa, F.,
813 Simonelli, F., TUDP (Telethon Undiagnosed Disease Program), Corton, M., Lualdi, S., Lanza,
814 F., Morana, G., Ayuso, C., Di Rocco, M., Filocamo, M., Banfi, S., Brunetti-Pierri, N., Superti-
815 Furga, A., & Rivolta, C. (2020). An Alu-mediated duplication in NMNAT1, involved in NAD
816 biosynthesis, causes a novel syndrome, SHILCA, affecting multiple tissues and organs. *Human*
817 *Molecular Genetics*, 29(13), 2250–2260. <https://doi.org/10.1093/hmg/ddaa112>

818

- 819 Bennett, Lea D., Martin Klein, Finny T. John, Bojana Radojevic, Kaylie Jones, and David G.
820 Birch. “Disease Progression in Patients with Autosomal Dominant Retinitis Pigmentosa Due to a
821 Mutation in Inosine Monophosphate Dehydrogenase 1 (IMPDH1).” *Translational Vision Science*
822 & *Technology* 9, no. 5 (April 23, 2020): 14. <https://doi.org/10.1167/tvst.9.5.14>.
823
- 824 Bowne, Sara J., Lori S. Sullivan, Sarah E. Mortimer, Lizbeth Hedstrom, Jingya Zhu, Catherine J.
825 Spellicy, Anisa I. Gire, et al. “Spectrum and Frequency of Mutations in IMPDH1 Associated
826 with Autosomal Dominant Retinitis Pigmentosa and Leber Congenital Amaurosis.” *Investigative*
827 *Ophthalmology & Visual Science* 47, no. 1 (January 1, 2006): 34. [https://doi.org/10.1167/iovs.05-](https://doi.org/10.1167/iovs.05-0868)
828 [0868](https://doi.org/10.1167/iovs.05-0868).
829
- 830 Brazill, Jennifer M, Chong Li, Yi Zhu, and R Grace Zhai. “NMNAT: It’s an NAD + Synthase...
831 It’s a Chaperone... It’s a Neuroprotector.” *Current Opinion in Genetics & Development* 44 (June
832 2017): 156–62. <https://doi.org/10.1016/j.gde.2017.03.014>.
833
- 834 Brzezinski, Joseph A, and Thomas A Reh. “Photoreceptor Cell Fate Specification in
835 Vertebrates,” 2015, 11.
836
- 837 Cambronne, X. A., M. L. Stewart, D. Kim, A. M. Jones-Brunette, R. K. Morgan, D. L. Farrens,
838 M. S. Cohen, and R. H. Goodman. “Biosensor Reveals Multiple Sources for Mitochondrial
839 NAD+.” *Science* 352, no. 6292 (June 17, 2016): 1474–77.
840 <https://doi.org/10.1126/science.aad5168>.
841
- 842 Cambronne, Xiaolu A., and W. Lee Kraus. “Location, Location, Location: Compartmentalization
843 of NAD+ Synthesis and Functions in Mammalian Cells.” *Trends in Biochemical Sciences* 45,
844 no. 10 (October 2020): 858–73. <https://doi.org/10.1016/j.tibs.2020.05.010>.
845
- 846 Cantó, Carles, Keir J. Menzies, and Johan Auwerx. “NAD+ Metabolism and the Control of
847 Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus.” *Cell*
848 *Metabolism* 22, no. 1 (July 2015): 31–53. <https://doi.org/10.1016/j.cmet.2015.05.023>.
849
- 850 Carty, Michael, Jay Kearney, Katharine A. Shanahan, Emily Hams, Ryoichi Sugisawa, Dymrna
851 Connolly, Ciara G. Doran, et al. “Cell Survival and Cytokine Release after Inflammasome
852 Activation Is Regulated by the Toll-IL-1R Protein SARM.” *Immunity* 50, no. 6 (June 2019):
853 1412-1424.e6. <https://doi.org/10.1016/j.immuni.2019.04.005>.
854
- 855 Chang, J., B. Zhang, H. Heath, N. Galjart, X. Wang, and J. Milbrandt. “Nicotinamide Adenine
856 Dinucleotide (NAD)-Regulated DNA Methylation Alters CCCTC-Binding Factor
857 (CTCF)/Cohesin Binding and Transcription at the BDNF Locus.” *Proceedings of the National*
858 *Academy of Sciences* 107, no. 50 (December 14, 2010): 21836–41.
859 <https://doi.org/10.1073/pnas.1002130107>.
860
- 861 Chiang, Pei-Wen, Juan Wang, Yang Chen, Quan Fu, Jing Zhong, Yanhua Chen, Xin Yi, et al.
862 “Exome Sequencing Identifies NMNAT1 Mutations as a Cause of Leber Congenital Amaurosis.”
863 *Nature Genetics* 44, no. 9 (September 2012): 972–74. <https://doi.org/10.1038/ng.2370>.

- 864 Chinchore, Yashodhan, Tedi Begaj, David Wu, Eugene Drokhlyansky, and Constance L Cepko.
865 “Glycolytic Reliance Promotes Anabolism in Photoreceptors.” *ELife* 6 (June 9, 2017): e25946.
866 <https://doi.org/10.7554/eLife.25946>.
867
- 868 Christiansen, J. R., S. Kolandaivelu, M. O. Bergo, and V. Ramamurthy. “RAS-Converting
869 Enzyme 1-Mediated Endoproteolysis Is Required for Trafficking of Rod Phosphodiesterase 6 to
870 Photoreceptor Outer Segments.” *Proceedings of the National Academy of Sciences* 108, no. 21
871 (May 24, 2011): 8862–66. <https://doi.org/10.1073/pnas.1103627108>.
872
- 873 Conforti, Laura, Lucie Janeckova, Diana Wagner, Francesca Mazzola, Lucia Cialabrini, Michele
874 Di Stefano, Giuseppe Orsomando, et al. “Reducing Expression of NAD⁺ Synthesizing Enzyme
875 NMNAT1 Does Not Affect the Rate of Wallerian Degeneration.” *The FEBS Journal* 278, no. 15
876 (2011): 2666–79. <https://doi.org/10.1111/j.1742-4658.2011.08193.x>.
877
- 878 Coppieters, Frauke, Anne Laure Todeschini, Takuro Fujimaki, Annelot Baert, Marieke Bruyne,
879 Caroline Cauwenbergh, Hannah Verdin, et al. “Hidden Genetic Variation in LCA9-Associated
880 Congenital Blindness Explained by 5'UTR Mutations and Copy-Number Variations of
881 NMNAT1.” *Human Mutation* 36, no. 12 (December 2015): 1188–96.
882 <https://doi.org/10.1002/humu.22899>.
883
- 884 Daum, Janine M, Özkan Keles, Sjoerd JB Holwerda, Hubertus Kohler, Filippo M Rijli, Michael
885 Stadler, and Botond Roska. “The Formation of the Light-Sensing Compartment of Cone
886 Photoreceptors Coincides with a Transcriptional Switch.” *ELife* 6 (November 6, 2017): e31437.
887 <https://doi.org/10.7554/eLife.31437>.
888
- 889 Donovan, M, and T G Cotter. “Caspase-Independent Photoreceptor Apoptosis in Vivo and
890 Differential Expression of Apoptotic Protease Activating Factor-1 and Caspase-3 during Retinal
891 Development.” *Cell Death & Differentiation* 9, no. 11 (November 2002): 1220–31.
892 <https://doi.org/10.1038/sj.cdd.4401105>.
893
- 894 Donovan, Maryanne, Francesca Doonan, and Thomas G. Cotter. “Decreased Expression of Pro-
895 Apoptotic Bcl-2 Family Members during Retinal Development and Differential Sensitivity to
896 Cell Death.” *Developmental Biology* 291, no. 1 (March 2006): 154–69.
897 <https://doi.org/10.1016/j.ydbio.2005.12.026>.
898
- 899 Doonan, Francesca, Maryanne Donovan, and Thomas G. Cotter. “Caspase-Independent
900 Photoreceptor Apoptosis in Mouse Models of Retinal Degeneration.” *The Journal of*
901 *Neuroscience* 23, no. 13 (July 2, 2003): 5723–31. [https://doi.org/10.1523/JNEUROSCI.23-13-](https://doi.org/10.1523/JNEUROSCI.23-13-05723.2003)
902 [05723.2003](https://doi.org/10.1523/JNEUROSCI.23-13-05723.2003).
903
- 904 Du, Jianhai, Haiwei Gu, Sally J Turner, Danijel Djukovic, Daniel Raftery, and James B Hurley.
905 “Metabolite Profiles of Rod Photoreceptor Cell Death in Mouse Retinal Degeneration Models.”
906 *Investigative Ophthalmology & Visual Science* 55, no. 13 (April 30, 2014): 4374–4374.
907

- 908 Du, Jianhai, Jonathan D. Linton, and James B. Hurley. “Probing Metabolism in the Intact Retina
909 Using Stable Isotope Tracers.” In *Methods in Enzymology*, 561:149–70. Elsevier, 2015.
910 <https://doi.org/10.1016/bs.mie.2015.04.002>.
911
- 912 Dvorianchikova, Galina, Seemungal, Rajeev, and Dmitry Ivanov. “DNA Methylation Dynamics
913 During the Differentiation of Retinal Progenitor Cells Into Retinal Neurons Reveal a Role for the
914 DNA Demethylation Pathway.” *Frontiers in Molecular Neuroscience* 12 (2019): 9.
915
- 916 Eblimit, Aiden, Smriti Agrawal Zaneveld, Wei Liu, Kandace Thomas, Keqing Wang, Yumei Li,
917 Graeme Mardon, and Rui Chen. “NMNAT1 E257K Variant, Associated with Leber Congenital
918 Amaurosis (LCA9), Causes a Mild Retinal Degeneration Phenotype.” *Experimental Eye
919 Research* 173 (August 2018): 32–43. <https://doi.org/10.1016/j.exer.2018.04.010>.
920
- 921 Etingof, R N. “De Novo Biosynthesis of Purines in the Retina: Evolutionary Aspects” 37, no. 1
922 (2001): 10.
923
- 924 Falk, Marni J, Qi Zhang, Eiko Nakamaru-Ogiso, Chitra Kannabiran, Zoe Fonseca-Kelly,
925 Christina Chakarova, Isabelle Audo, et al. “NMNAT1 Mutations Cause Leber Congenital
926 Amaurosis.” *Nature Genetics* 44, no. 9 (September 2012): 1040–45.
927 <https://doi.org/10.1038/ng.2361>.
928
- 929 Figley, Matthew D., Weixi Gu, Jeffrey D. Nanson, Yun Shi, Yo Sasaki, Katie Cunnea,
930 Alpeshkumar K. Malde, et al. “SARM1 Is a Metabolic Sensor Activated by an Increased
931 NMN/NAD⁺ Ratio to Trigger Axon Degeneration.” *Neuron*, March 2021, S0896627321000830.
932 <https://doi.org/10.1016/j.neuron.2021.02.009>.
933
- 934 Finding of Rare Disease Genes (FORGE) Canada Consortium, Robert K Koenekoop, Hui Wang,
935 Jacek Majewski, Xia Wang, Irma Lopez, Huanan Ren, et al. “Mutations in NMNAT1 Cause
936 Leber Congenital Amaurosis and Identify a New Disease Pathway for Retinal Degeneration.”
937 *Nature Genetics* 44, no. 9 (September 2012): 1035–39. <https://doi.org/10.1038/ng.2356>.
938
- 939 Furuta, Yasuhide, Oleg Lagutin, Brigid L M Hogan, and Guillermo C Oliver. “Retina- and
940 Ventral Forebrain-specific Cre Recombinase Activity in Transgenic Mice,” n.d., 3.
941
- 942 Greenwald, Scott H, Emily E Brown, Michael J Scandura, Erin Hennessey, Raymond Farmer,
943 Jianhai Du, Yekai Wang, and Eric A Pierce. “Mutant NMNAT1 Leads to a Retina-Specific
944 Decrease of NAD⁺ Accompanied by Increased Poly(ADP-Ribose) in a Mouse Model of
945 NMNAT1 -Associated Retinal Degeneration.” *Human Molecular Genetics*, March 11, 2021,
946 ddab070. <https://doi.org/10.1093/hmg/ddab070>.
947
- 948 Greenwald, Scott H., Emily E. Brown, Michael J. Scandura, Erin Hennessey, Raymond Farmer,
949 Basil S. Pawlyk, Ru Xiao, Luk H. Vandenberghe, and Eric A. Pierce. “Gene Therapy Preserves
950 Retinal Structure and Function in a Mouse Model of NMNAT1-Associated Retinal
951 Degeneration.” *Molecular Therapy - Methods & Clinical Development* 18 (September 2020):
952 582–94. <https://doi.org/10.1016/j.omtm.2020.07.003>.
953

- 954 Greenwald, Scott H., Jeremy R. Charette, Magdalena Staniszewska, Lan Ying Shi, Steve D.M.
955 Brown, Lisa Stone, Qin Liu, et al. “Mouse Models of NMNAT1-Leber Congenital Amaurosis
956 (LCA9) Recapitulate Key Features of the Human Disease.” *The American Journal of Pathology*
957 186, no. 7 (July 2016): 1925–38. <https://doi.org/10.1016/j.ajpath.2016.03.013>.
958
- 959 Grenell, A., Wang, Y., Yam, M., Swarup, A., Dilan, T. L., Hauer, A., Linton, J. D., Philp, N. J.,
960 Gregor, E., Zhu, S., Shi, Q., Murphy, J., Guan, T., Lohner, D., Kolandaivelu, S., Ramamurthy,
961 V., Goldberg, A. F. X., Hurley, J. B., & Du, J. (2019). Loss of MPC1 reprograms retinal
962 metabolism to impair visual function. *Proceedings of the National Academy of Sciences*, 116(9),
963 3530–3535. <https://doi.org/10.1073/pnas.1812941116>
964
- 965 Gutierrez, Kimberley D., Michael A. Davis, Brian P. Daniels, Tayla M. Olsen, Pooja Ralli-Jain,
966 Stephen W. G. Tait, Michael Gale, and Andrew Oberst. “MLKL Activation Triggers NLRP3-
967 Mediated Processing and Release of IL-1 β Independently of Gasdermin-D.” *The Journal of*
968 *Immunology* 198, no. 5 (March 1, 2017): 2156–64. <https://doi.org/10.4049/jimmunol.1601757>.
969
- 970 Houtkooper, Riekelt H., Carles Cantó, Ronald J. Wanders, and Johan Auwerx. “The Secret Life
971 of NAD⁺: An Old Metabolite Controlling New Metabolic Signaling Pathways.” *Endocrine*
972 *Reviews* 31, no. 2 (April 2010): 194–223. <https://doi.org/10.1210/er.2009-0026>.
973
- 974 Kanow, Mark A, Michelle M Giarmarco, Connor SR Jankowski, Kristine Tsantilas, Abbi L
975 Engel, Jianhai Du, Jonathan D Linton, et al. “Biochemical Adaptations of the Retina and Retinal
976 Pigment Epithelium Support a Metabolic Ecosystem in the Vertebrate Eye.” *ELife* 6 (September
977 13, 2017): e28899. <https://doi.org/10.7554/eLife.28899>.
978
- 979 Kayagaki, Nobuhiko, Bettina L. Lee, Irma B. Stowe, Opher S. Kornfeld, Karen O’Rourke,
980 Kathleen M. Mirrashidi, Benjamin Haley, et al. “IRF2 Transcriptionally Induces GSDMD
981 Expression for Pyroptosis.” *Science Signaling* 12, no. 582 (May 21, 2019): eaax4917.
982 <https://doi.org/10.1126/scisignal.aax4917>.
983
- 984 Kim, Daehwan, Ben Langmead, and Steven L Salzberg. “HISAT: A Fast Spliced Aligner with
985 Low Memory Requirements.” *Nature Methods* 12, no. 4 (April 2015): 357–60.
986 <https://doi.org/10.1038/nmeth.3317>.
987
- 988 Kumaran, Neruban, Anthony T Moore, Richard G Weleber, and Michel Michaelides. “Leber
989 Congenital Amaurosis/Early-Onset Severe Retinal Dystrophy: Clinical Features, Molecular
990 Genetics and Therapeutic Interventions.” *British Journal of Ophthalmology* 101, no. 9
991 (September 2017): 1147–54. <https://doi.org/10.1136/bjophthalmol-2016-309975>.
992
- 993 Kuribayashi, Hiroshi, Yukihiro Baba, Toshiro Iwagawa, Eisuke Arai, Akira Murakami, and
994 Sumiko Watanabe. “Roles of Nmnat1 in the Survival of Retinal Progenitors through the
995 Regulation of Pro-Apoptotic Gene Expression via Histone Acetylation.” *Cell Death & Disease* 9,
996 no. 9 (August 30, 2018). <https://doi.org/10.1038/s41419-018-0907-0>.
997
- 998 Lin, Jonathan B., Shunsuke Kubota, Norimitsu Ban, Mitsukuni Yoshida, Andrea Santeford,
999 Abdoulaye Sene, Rei Nakamura, et al. “NAMPT-Mediated NAD⁺ Biosynthesis Is Essential for

- 1000 Vision In Mice.” *Cell Reports* 17, no. 1 (September 2016): 69–85.
1001 <https://doi.org/10.1016/j.celrep.2016.08.073>.
1002
1003 Love, Michael I, Wolfgang Huber, and Simon Anders. “Moderated Estimation of Fold Change
1004 and Dispersion for RNA-Seq Data with DESeq2.” *Genome Biology* 15, no. 12 (December 2014):
1005 550. <https://doi.org/10.1186/s13059-014-0550-8>.
1006
1007 Lundt, Samuel, Nannan Zhang, Jun-Liszt Li, Zhe Zhang, Li Zhang, Xiaowan Wang, Ruisi Bao,
1008 et al. “Metabolomic and Transcriptional Profiling Reveals Bioenergetic Stress and Activation of
1009 Cell Death and Inflammatory Pathways in Vivo after Neuronal Deletion of NAMPT.” *Journal of*
1010 *Cerebral Blood Flow & Metabolism*, February 9, 2021, 0271678X2199262.
1011 <https://doi.org/10.1177/0271678X21992625>.
1012
1013 McKenzie, Brienne A. “Fiery Cell Death: Pyroptosis in the Central Nervous System.” *Trends in*
1014 *Neurosciences*, n.d., 19.
1015
1016 Miao, Edward A., Jayant V. Rajan, and Alan Aderem. “Caspase-1-Induced Pyroptotic Cell
1017 Death: Caspase-1-Induced Pyroptotic Cell Death.” *Immunological Reviews* 243, no. 1
1018 (September 2011): 206–14. <https://doi.org/10.1111/j.1600-065X.2011.01044.x>.
1019
1020 Mori, Valerio, Adolfo Amici, Francesca Mazzola, Michele Di Stefano, Laura Conforti, Giulio
1021 Magni, Silverio Ruggieri, Nadia Raffaelli, and Giuseppe Orsomando. “Metabolic Profiling of
1022 Alternative NAD Biosynthetic Routes in Mouse Tissues.” Edited by Valerie de Crécy-Lagard.
1023 *PLoS ONE* 9, no. 11 (November 25, 2014): e113939.
1024 <https://doi.org/10.1371/journal.pone.0113939>.
1025
1026 Mukherjee, Piyali, Clayton W. Winkler, Katherine G. Taylor, Tyson A. Woods, Vinod Nair,
1027 Burhan A. Khan, and Karin E. Peterson. “SARM1, Not MyD88, Mediates TLR7/TLR9-Induced
1028 Apoptosis in Neurons.” *The Journal of Immunology* 195, no. 10 (November 15, 2015): 4913–21.
1029 <https://doi.org/10.4049/jimmunol.1500953>.
1030
1031 Müller, Tammo, Christin Dewitz, Jessica Schmitz, Anna Sophia Schröder, Jan Hinrich Bräsen,
1032 Brent R. Stockwell, James M. Murphy, Ulrich Kunzendorf, and Stefan Krautwald. “Necroptosis
1033 and Ferroptosis Are Alternative Cell Death Pathways That Operate in Acute Kidney Failure.”
1034 *Cellular and Molecular Life Sciences* 74, no. 19 (October 2017): 3631–45.
1035 <https://doi.org/10.1007/s00018-017-2547-4>.
1036
1037 Murakami, Y., H. Matsumoto, M. Roh, J. Suzuki, T. Hisatomi, Y. Ikeda, J. W. Miller, and D. G.
1038 Vavvas. “Receptor Interacting Protein Kinase Mediates Necrotic Cone but Not Rod Cell Death
1039 in a Mouse Model of Inherited Degeneration.” *Proceedings of the National Academy of Sciences*
1040 109, no. 36 (September 4, 2012): 14598–603. <https://doi.org/10.1073/pnas.1206937109>.
1041
1042 Nash, Benjamin M., Richard Symes, Himanshu Goel, Marcel E. Dinger, Bruce Bennetts, John R.
1043 Grigg, and Robyn V. Jamieson. “NMNAT1 Variants Cause Cone and Cone-Rod Dystrophy.”
1044 *European Journal of Human Genetics* 26, no. 3 (March 2018): 428–33.
1045 <https://doi.org/10.1038/s41431-017-0029-7>.

- 1046
1047 Navas, Lola E., and Amancio Carnero. "NAD⁺ Metabolism, Stemness, the Immune Response,
1048 and Cancer." *Signal Transduction and Targeted Therapy* 6, no. 1 (December 2021): 2.
1049 <https://doi.org/10.1038/s41392-020-00354-w>.
1050
1051 Newton, K., D. L. Dugger, K. E. Wickliffe, N. Kapoor, M. C. de Almagro, D. Vucic, L.
1052 Komuves, et al. "Activity of Protein Kinase RIPK3 Determines Whether Cells Die by
1053 Necroptosis or Apoptosis." *Science* 343, no. 6177 (March 21, 2014): 1357–60.
1054 <https://doi.org/10.1126/science.1249361>.
1055
1056 Ng, Soo Khai, John PM Wood, Glyn Chidlow, Guoge Han, Thaksaon Kittipassorn, Daniel J
1057 Peet, and Robert J Casson. "Cancer-like Metabolism of the Mammalian Retina: Mammalian
1058 Retina Metabolism." *Clinical & Experimental Ophthalmology* 43, no. 4 (May 2015): 367–76.
1059 <https://doi.org/10.1111/ceo.12462>.
1060
1061 Nikiforov, Andrey, Veronika Kulikova, and Mathias Ziegler. "The Human NAD Metabolome:
1062 Functions, Metabolism and Compartmentalization." *Critical Reviews in Biochemistry and*
1063 *Molecular Biology* 50, no. 4 (July 4, 2015): 284–97.
1064 <https://doi.org/10.3109/10409238.2015.1028612>.
1065
1066 Oakey, Lucy A., Rachel S. Fletcher, Yasir S. Elhassan, David M. Cartwright, Craig L. Doig,
1067 Antje Garten, Alpesh Thakker, et al. "Metabolic Tracing Reveals Novel Adaptations to Skeletal
1068 Muscle Cell Energy Production Pathways in Response to NAD + Depletion." *Wellcome Open*
1069 *Research* 3 (2018): 147. <https://doi.org/10.12688/wellcomeopenres.14898.2>.
1070
1071 Perrault, Isabelle, Sylvain Hanein, Xavier Zanlonghi, Valérie Serre, Michael Nicouleau, Sabine
1072 Defoort-Delhemmes, Nathalie Delphin, et al. "Mutations in NMNAT1 Cause Leber Congenital
1073 Amaurosis with Early-Onset Severe Macular and Optic Atrophy." *Nature Genetics* 44, no. 9
1074 (September 2012): 975–77. <https://doi.org/10.1038/ng.2357>.
1075
1076 Perteau, Mihaela, Daehwan Kim, Geo M Perteau, Jeffrey T Leek, and Steven L Salzberg.
1077 "Transcript-Level Expression Analysis of RNA-Seq Experiments with HISAT, StringTie and
1078 Ballgown." *Nature Protocols* 11, no. 9 (August 11, 2016): 1650–67.
1079 <https://doi.org/10.1038/nprot.2016.095>.
1080
1081 Perteau, Mihaela, Geo M Perteau, Corina M Antonescu, Tsung-Cheng Chang, Joshua T Mendell,
1082 and Steven L Salzberg. "StringTie Enables Improved Reconstruction of a Transcriptome from
1083 RNA-Seq Reads." *Nature Biotechnology* 33, no. 3 (March 2015): 290–95.
1084 <https://doi.org/10.1038/nbt.3122>.
1085
1086 Preyat, Nicolas, and Oberdan Leo. "Complex Role of Nicotinamide Adenine Dinucleotide in the
1087 Regulation of Programmed Cell Death Pathways." *Biochemical Pharmacology* 101 (February
1088 2016): 13–26. <https://doi.org/10.1016/j.bcp.2015.08.110>.
1089

- 1090 Raeisossadati, Reza, Merari F. R. Ferrari, Alexandre Hiroaki Kihara, Issam AlDiri, and Jeffrey
1091 M. Gross. “Epigenetic Regulation of Retinal Development.” *Epigenetics & Chromatin* 14, no. 1
1092 (December 2021): 11. <https://doi.org/10.1186/s13072-021-00384-w>.
1093
- 1094 Rhee, K-D, J Yu, C Y Zhao, G Fan, and X-J Yang. “Dnmt1-Dependent DNA Methylation Is
1095 Essential for Photoreceptor Terminal Differentiation and Retinal Neuron Survival.” *Cell Death &
1096 Disease* 3, no. 11 (November 2012): e427–e427. <https://doi.org/10.1038/cddis.2012.165>.
1097
- 1098 Sanman, Laura E, Yu Qian, Nicholas A Eisele, Tessie M Ng, Wouter A van der Linden, Denise
1099 M Monack, Eranthie Weerapana, and Matthew Bogoy. “Disruption of Glycolytic Flux Is a
1100 Signal for Inflammasome Signaling and Pyroptotic Cell Death.” *ELife* 5 (March 24, 2016):
1101 e13663. <https://doi.org/10.7554/eLife.13663>.
1102
- 1103 Sasaki, Yo, Thomas M. Engber, Robert O. Hughes, Matthew D. Figley, Tong Wu, Todd
1104 Bosanac, Rajesh Devraj, Jeffrey Milbrandt, Raul Krauss, and Aaron DiAntonio. “CADPR Is a
1105 Gene Dosage-Sensitive Biomarker of SARM1 Activity in Healthy, Compromised, and
1106 Degenerating Axons.” *Experimental Neurology* 329 (July 2020): 113252.
1107 <https://doi.org/10.1016/j.expneurol.2020.113252>.
1108
- 1109 Sasaki, Yo, Hiroki Kakita, Shunsuke Kubota, Abdoulaye Sene, Tae Jun Lee, Norimitsu Ban,
1110 Zhenyu Dong, et al. “SARM1 Depletion Rescues NMNAT1-Dependent Photoreceptor Cell
1111 Death and Retinal Degeneration.” *ELife* 9 (October 27, 2020): e62027.
1112 <https://doi.org/10.7554/eLife.62027>.
1113
- 1114 Sasaki, Yo, Zachary Margolin, Benjamin Borgo, James J. Havranek, and Jeffrey Milbrandt.
1115 “Characterization of Leber Congenital Amaurosis-Associated NMNAT1 Mutants.” *Journal of
1116 Biological Chemistry* 290, no. 28 (July 2015): 17228–38.
1117 <https://doi.org/10.1074/jbc.M115.637850>.
1118
- 1119 Sato, K., S. Li, W. C. Gordon, J. He, G. I. Liou, J. M. Hill, G. H. Travis, N. G. Bazan, and M.
1120 Jin. “Receptor Interacting Protein Kinase-Mediated Necrosis Contributes to Cone and Rod
1121 Photoreceptor Degeneration in the Retina Lacking Interphotoreceptor Retinoid-Binding Protein.”
1122 *Journal of Neuroscience* 33, no. 44 (October 30, 2013): 17458–68.
1123 <https://doi.org/10.1523/JNEUROSCI.1380-13.2013>.
1124
- 1125 Seritrakul, Pawat, and Jeffrey M. Gross. “Tet-Mediated DNA Hydroxymethylation Regulates
1126 Retinal Neurogenesis by Modulating Cell-Extrinsic Signaling Pathways.” Edited by Wolf Reik.
1127 *PLOS Genetics* 13, no. 9 (September 19, 2017): e1006987.
1128 <https://doi.org/10.1371/journal.pgen.1006987>.
1129
- 1130 Singh, Ratnesh K., Ramya K. Mallela, Abigail Hayes, Nicholas R. Dunham, Morgan E. Hedden,
1131 Raymond A. Enke, Robert N. Fariss, Hal Sternberg, Michael D. West, and Igor O. Nasonkin.
1132 “Dnmt1, Dnmt3a and Dnmt3b Cooperate in Photoreceptor and Outer Plexiform Layer
1133 Development in the Mammalian Retina.” *Experimental Eye Research* 159 (June 2017): 132–46.
1134 <https://doi.org/10.1016/j.exer.2016.11.014>.
1135

- 1136 Sinha, Tirthankar, Jianhai Du, Mustafa S. Makia, James B. Hurley, Muna I. Naash, and Muayyad
1137 R. Al-Ubaidi. “Absence of Retbindin Blocks Glycolytic Flux, Disrupts Metabolic Homeostasis,
1138 and Leads to Photoreceptor Degeneration.” *Proceedings of the National Academy of Sciences*
1139 118, no. 6 (February 9, 2021): e2018956118. <https://doi.org/10.1073/pnas.2018956118>.
1140
- 1141 Song, Tanjing, Leixiang Yang, Neha Kabra, Lihong Chen, John Koomen, Eric B. Haura, and
1142 Jiandong Chen. “The NAD⁺ Synthesis Enzyme Nicotinamide Mononucleotide
1143 Adenylyltransferase (NMNAT1) Regulates Ribosomal RNA Transcription.” *Journal of*
1144 *Biological Chemistry* 288, no. 29 (July 19, 2013): 20908–17.
1145 <https://doi.org/10.1074/jbc.M113.470302>.
1146
- 1147 Svoboda, Petr, Edita Krizova, Sarka Sestakova, Kamila Vapenkova, Zdenek Knejzlik, Silvie
1148 Rimpelova, Diana Rayova, et al. “Nuclear Transport of Nicotinamide Phosphoribosyltransferase
1149 Is Cell Cycle–Dependent in Mammalian Cells, and Its Inhibition Slows Cell Growth.” *Journal of*
1150 *Biological Chemistry* 294, no. 22 (May 2019): 8676–89.
1151 <https://doi.org/10.1074/jbc.RA118.003505>.
1152
- 1153 Swanson, Karen V., Meng Deng, and Jenny P.-Y. Ting. “The NLRP3 Inflammasome: Molecular
1154 Activation and Regulation to Therapeutics.” *Nature Reviews Immunology* 19, no. 8 (August
1155 2019): 477–89. <https://doi.org/10.1038/s41577-019-0165-0>.
1156
- 1157 Swaroop, Anand, Douglas Kim, and Douglas Forrest. “Transcriptional Regulation of
1158 Photoreceptor Development and Homeostasis in the Mammalian Retina.” *Nature Reviews*
1159 *Neuroscience* 11, no. 8 (August 2010): 563–76. <https://doi.org/10.1038/nrn2880>.
1160
- 1161 Vandenabeele, Peter, Lorenzo Galluzzi, Tom Vanden Berghe, and Guido Kroemer. “Molecular
1162 Mechanisms of Necroptosis: An Ordered Cellular Explosion.” *Nature Reviews Molecular Cell*
1163 *Biology* 11, no. 10 (October 2010): 700–714. <https://doi.org/10.1038/nrm2970>.
1164
- 1165 Wang, Xiaolin, Yu Fang, Rongsheng Liao, and Tao Wang. “Targeted Deletion of Nmnat1 in
1166 Mouse Retina Leads to Early Severe Retinal Dystrophy.” Preprint. *Developmental Biology*,
1167 October 29, 2017. <https://doi.org/10.1101/210757>.
1168
- 1169 Yam, M., Engel, A. L., Wang, Y., Zhu, S., Hauer, A., Zhang, R., Lohner, D., Huang, J.,
1170 Dinterman, M., Zhao, C., Chao, J. R., & Du, J. (2019). Proline mediates metabolic
1171 communication between retinal pigment epithelial cells and the retina. *Journal of Biological*
1172 *Chemistry*, 294(26), 10278–10289. <https://doi.org/10.1074/jbc.RA119.007983>
1173
- 1174 Zhang, Rui, Weiyong Shen, Jianhai Du, and Mark C. Gillies. “Selective Knockdown of
1175 Hexokinase 2 in Rods Leads to Age-Related Photoreceptor Degeneration and Retinal Metabolic
1176 Remodeling.” *Cell Death & Disease* 11, no. 10 (October 2020): 885.
1177 <https://doi.org/10.1038/s41419-020-03103-7>.
1178
- 1179 Zhang, Tong, Jhoanna G. Berrocal, Jie Yao, Michelle E. DuMond, Raga Krishnakumar, Donald
1180 D. Ruhl, Keun Woo Ryu, Matthew J. Gamble, and W. Lee Kraus. “Regulation of Poly(ADP-
1181 Ribose) Polymerase-1-Dependent Gene Expression through Promoter-Directed Recruitment of a

- 1182 Nuclear NAD⁺ Synthase*.” *Journal of Biological Chemistry* 287, no. 15 (April 2012): 12405–
1183 16. <https://doi.org/10.1074/jbc.M111.304469>.
1184
1185 Zhao, Zhi Ying, Xu Jie Xie, Wan Hua Li, Jun Liu, Zhe Chen, Ben Zhang, Ting Li, et al. “A Cell-
1186 Permeant Mimetic of NMN Activates SARM1 to Produce Cyclic ADP-Ribose and Induce Non-
1187 Apoptotic Cell Death.” *IScience* 15 (May 31, 2019): 452–66.
1188 <https://doi.org/10.1016/j.isci.2019.05.001>.
1189
1190 Zhu, Siyan, Michelle Yam, Yekai Wang, Jonathan D. Linton, Allison Grenell, James B. Hurley,
1191 and Jianhai Du. “Impact of Euthanasia, Dissection and Postmortem Delay on Metabolic Profile
1192 in Mouse Retina and RPE/Choroid.” *Experimental Eye Research* 174 (September 2018): 113–20.
1193 <https://doi.org/10.1016/j.exer.2018.05.032>.
1194